We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
AUM
$172M
AUM Growth
-$37.3M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PHAT icon
1
Phathom Pharmaceuticals
PHAT
$708M
$68.7M 39.92%
2,067,861
PCVX icon
2
Vaxcyte
PCVX
$7.81B
$50.1M 29.15%
1,887,478
MRUS
3
DELISTED
Merus
MRUS
$28M 16.3%
1,600,000
CMPI
4
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$21.9M 12.73%
1,501,716
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.27M 1.9%
1,570,000

Similar funds

Medicxi Ventures Management's Q4 2020 Portfolio in Review

As of Q4 2020, Medicxi Ventures Management held 5 positions worth $172M, down 18% from $209M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2020: portfolio turnover was 0%. Medicxi Ventures Management opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's ten largest holdings make up 100% of its $172M portfolio in Q4 2020.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q4 2020.
  • Medicxi Ventures Management's portfolio value fell 18% quarter-over-quarter to $172M.

Based on Medicxi Ventures Management's 13F filing for Q4 2020, filed 12 Feb 2021.